Italy Oral Anti-Diabetic Drug Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 705.48 Million |
| Market Size (2029) | USD 837.88 Million |
| CAGR (2024 - 2029) | 3.50 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Italy Oral Anti-Diabetic Drug Market Analysis
The Italy Oral Anti-Diabetic Drug Market size is estimated at USD 705.48 million in 2024, and is expected to reach USD 837.88 million by 2029, growing at a CAGR of 3.5% during the forecast period (2024-2029).
The rising prevalence of diabetes in Italy has become a significant health concern, driving the demand for oral anti-diabetes medications. With lifestyle changes, including sedentary behavior, unhealthy eating habits, and an aging population, Italy has witnessed a steady increase in the number of individuals diagnosed with diabetes. According to recent statistics, Italy ranks among the European countries with a high prevalence of diabetes, with both type 1 and type 2 diabetes contributing to the burden of the disease.
As the diabetes population continues to grow in Italy, there is a parallel surge in the need for effective management and treatment options. Oral anti-diabetes medications play a crucial role in controlling blood sugar levels and preventing complications associated with diabetes. These medications are favored by many patients due to their convenience, ease of administration, and ability to improve glycemic control.
The demand for oral anti-diabetes medications reflects the necessity for accessible and efficient treatments to combat the escalating diabetes epidemic in Italy. Healthcare providers are increasingly prescribing these medications to help patients manage their condition and reduce the risk of complications such as cardiovascular disease, kidney failure, and nerve damage.
Furthermore, the rising awareness of diabetes-related complications and the importance of early intervention have led to greater emphasis on medication adherence and regular monitoring among patients. This emphasis underscores the significance of oral anti-diabetes medications in supporting long-term disease management and improving overall health outcomes for individuals living with diabetes in Italy. As the diabetes population continues to grow, addressing the demand for oral anti-diabetes medications remains paramount in ensuring effective diabetes care and reducing the burden of the disease on individuals and the healthcare system.
Italy Oral Anti-Diabetic Drug Market Trends
Sodium-glucose Cotransport-2 (SGLT-2) inhibitor Segment Occupied the Highest Market Share in the Italy Oral Anti-Diabetic Drugs Market in current year
In terms of revenue, the Sodium-glucose Cotransport-2 (SGLT-2) inhibitor Segment is anticipated to lead the Italy Oral Anti-Diabetic Drugs Market and post a CAGR of over 11% during the course of the forecast year.
A class of pharmaceuticals known as the Sodium-glucose Cotransport-2 (SGLT-2) inhibitor Segment is used to treat type 2 diabetes, and several of these medications have also been licensed to treat obesity. The fact that this family of medications has a reduced risk of producing hypoglycemia than older insulin secretagogues like sulfonylureas or meglitinides is one of their advantages.
The National Health Program is set up into fundamental tiers of aid, each of which can be defined uniquely in each location. LEAs are how the National Health Program is organized. All medical aid programs provided by the INHS to citizens, with or without a patient's income-based partial contribution, are defined by LEAs. One of the major problems facing the Italian healthcare system is diabetes, a serious health issue.
The development of novel medications to give diabetic patients more treatment options has been driven by the disease's increasing incidence, prevalence, and progressive nature. Some of the potential prospects for the companies in the Italian diabetes medications market include the introduction of several new products, expanding international research collaborations for technological advancement, and raising public awareness of diabetes.
Increasing Diabetes Population in Italy is driving the market.
Italy witnessed an alarming increase in the prevalence of diabetes in recent years. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as oral anti-diabetic medication or ingestion of additional carbohydrates by monitoring their blood glucose levels. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs.
Oral anti-diabetic medications have been made available globally and are advised for usage when type 2 diabetes therapy needs to be escalated along with lifestyle modification. Due to the wide range of efficacy, safety, and modes of action that oral medicines have, they are frequently the first treatments employed in the treatment of type 2 diabetes. Diabetes patients can minimize their risk of complications and maintain control of their illness with the use of anti-diabetic medications.
Throughout the rest of their lives, people with diabetes may need to take anti-diabetic medications to manage their blood sugar levels and prevent hypo and hyperglycemia. Oral anti-diabetic medications have higher acceptance than insulin, which improves adherence to therapy. They also have the advantages of easier control and lower costs. The Italian National Healthcare Service (NHS) ensures universal coverage for all citizens. People living with diabetes have access, with no out-of-pocket expenditure, to all the medicines, devices, and medical services they need.
Overall, Italy has a well-developed system of diabetes care, with numerous diabetes centers throughout the country and treatment free at the point of delivery. The Italian health system is highly decentralized, with most administrative and organizational powers held by the Regions. The National Diabetes Plan defines priorities and provides guidelines to improve the quality of diabetes care with a patient-centered focus.
It is therefore anticipated to drive the category expansion during the forecast period because of the aforementioned factors.
Italy Oral Anti-Diabetic Drug Industry Overview
The Italy oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.
Italy Oral Anti-Diabetic Drug Market Leaders
-
Sanofi
-
Eli Lily
-
Astellas
-
Astrazeneca
-
Janseen
*Disclaimer: Major Players sorted in no particular order
Italy Oral Anti-Diabetic Drug Market News
- December 2023: Boehringer Ingelheim and Eli Lilly have obtained authorization from the European Commission (EC) for the use of Jardiance (empagliflozin) 10mg and 25mg tablets in children aged 10 years and older to treat inadequately managed type 2 diabetes mellitus (T2D) in conjunction with diet and exercise within the European Union (EU).
- March 2022: Eli Lilly and Boehringer Ingelheim gained approval for heart failure treatment from the EU for sodium-glucose co-transporter-2-inhibitor (SGLT2-I) and Jardiance (empagliflozin).
Italy Oral Anti-Diabetic Drug Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028)
- 5.1.1 Biguanides
- 5.1.1.1 Metformin
- 5.1.2 Alpha-Glucosidase Inhibitors
- 5.1.2.1 Alpha-Glucosidase Inhibitors
- 5.1.3 Dopamine D2 receptor agonist
- 5.1.3.1 Bromocriptin
- 5.1.4 SGLT-2 inhibitors
- 5.1.4.1 Invokana (Canagliflozin)
- 5.1.4.2 Jardiance (Empagliflozin)
- 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
- 5.1.4.4 Suglat (Ipragliflozin)
- 5.1.5 DPP-4 inhibitors
- 5.1.5.1 Onglyza (Saxagliptin)
- 5.1.5.2 Tradjenta (Linagliptin)
- 5.1.5.3 Vipidia/Nesina(Alogliptin)
- 5.1.5.4 Galvus (Vildagliptin)
- 5.1.6 Sulfonylureas
- 5.1.6.1 Sulfonylureas
- 5.1.7 Meglitinides
- 5.1.7.1 Meglitinides
6. MARKET INDICATORS
- 6.1 Type-1 Diabetic Population (2017 - 2028)
- 6.2 Type-2 Diabetic Population (2017 - 2028)
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Takeda
- 7.1.2 Novo Nordisk
- 7.1.3 Pfizer
- 7.1.4 Eli Lilly
- 7.1.5 Janssen Pharmaceuticals
- 7.1.6 Astellas
- 7.1.7 Boehringer Ingelheim
- 7.1.8 Merck And Co.
- 7.1.9 AstraZeneca
- 7.1.10 Bristol Myers Squibb
- 7.1.11 Novartis
- 7.1.12 Sanofi
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Italy Oral Anti-Diabetic Drug Industry Segmentation
Orally administered antihyperglycemic drugs reduce blood glucose levels. The medications function by boosting the release of insulin from the pancreas, improving the body's response to insulin, or delaying the absorption of glucose in the intestines after meals. The Italy Oral Anti-Diabetic Drug Market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.
| Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028) | Biguanides | Metformin |
| Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028) | Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors |
| Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028) | Dopamine D2 receptor agonist | Bromocriptin |
| Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028) | SGLT-2 inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028) | DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028) | Sulfonylureas | Sulfonylureas |
| Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028) | Meglitinides | Meglitinides |
Italy Oral Anti-Diabetic Drug Market Research FAQs
How big is the Italy Oral Anti-Diabetic Drug Market?
The Italy Oral Anti-Diabetic Drug Market size is expected to reach USD 705.48 million in 2024 and grow at a CAGR of 3.5% to reach USD 837.88 million by 2029.
What is the current Italy Oral Anti-Diabetic Drug Market size?
In 2024, the Italy Oral Anti-Diabetic Drug Market size is expected to reach USD 705.48 million.
Who are the key players in Italy Oral Anti-Diabetic Drug Market?
Sanofi, Eli Lily, Astellas, Astrazeneca and Janseen are the major companies operating in the Italy Oral Anti-Diabetic Drug Market.
What years does this Italy Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?
In 2023, the Italy Oral Anti-Diabetic Drug Market size was estimated at USD 680.79 million. The report covers the Italy Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Italy Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Italy Oral Anti-Diabetic Drug Industry Report
Statistics for the 2024 Italy Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Italy Oral Anti-Diabetic Drug analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
